JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Elenco Azioni・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

13.15 -1.72

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.88

Massimo

13.4

Metriche Chiave
By Trading Economics
Entrata	227M
Vendite	139M
P/E Media del settore	5.076 67.147
Margine di Profitto	163.843
Dipendenti	1,796
EBITDA	1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+48.81% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2.3B
Apertura precedente	14.87
Chiusura precedente	13.15

Notizie sul Sentiment di mercato

By Acuity

50%

175 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

14.24 / 14.78 Supporto e resistenza

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 mag 2026, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 mag 2026, 20:40 UTC

Acquisizioni, Fusioni, Takeovers

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 mag 2026, 18:37 UTC

I principali Market Mover

Senseonic Shares Slide on Underwritten Offering Price

1 mag 2026, 16:46 UTC

I principali Market Mover

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 mag 2026, 20:42 UTC

Utili

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 mag 2026, 19:18 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 mag 2026, 19:13 UTC

Discorsi di Mercato

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 mag 2026, 18:36 UTC

Utili

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 mag 2026, 18:35 UTC

Utili

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mag 2026, 18:28 UTC

Utili

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 mag 2026, 18:27 UTC

Discorsi di Mercato

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 mag 2026, 18:14 UTC

Acquisizioni, Fusioni, Takeovers

Barclays Completes Acquisition of Best Egg

1 mag 2026, 18:04 UTC

Utili

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 mag 2026, 17:43 UTC

Discorsi di Mercato

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 mag 2026, 17:37 UTC

Discorsi di Mercato

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 mag 2026, 17:30 UTC

Discorsi di Mercato

Utili

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 mag 2026, 17:28 UTC

Discorsi di Mercato

Utili

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 mag 2026, 17:21 UTC

Discorsi di Mercato

Utili

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 mag 2026, 17:19 UTC

Discorsi di Mercato

Principali Notizie su Eventi

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 mag 2026, 16:38 UTC

Discorsi di Mercato

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 mag 2026, 16:23 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 mag 2026, 16:15 UTC

Utili

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

1 mag 2026, 16:11 UTC

Discorsi di Mercato

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

1 mag 2026, 16:04 UTC

Utili

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

48.81% in crescita

Previsioni per 12 mesi

Media 20 USD 48.81%

Alto 20 USD

Basso 20 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

14.24 / 14.78Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

175 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.